Millennium Offers AnorMED $515 Mil.; Outbids Genzyme By 35%
This article was originally published in The Pink Sheet Daily
Executive Summary
AnorMED’s Phase III Mozobil would be promoted by Millennium’s Velcade sales force.
You may also be interested in...
Genzyme Raises Bid For AnorMED, Emphasizing Market Advantage For Mozobil
Latest bid is 12.5% higher than Millennium’s, but the firm will have three days to match it if needed.
Genzyme Raises Bid For AnorMED, Emphasizing Market Advantage For Mozobil
Latest bid is 12.5% higher than Millennium’s, but the firm will have three days to match it if needed.
Genzyme Bids For AnorMED Eyeing Stem Cell Transplantation Technology
Genzyme appeals directly to shareholders after rejection from AnorMed’s board of directors.